The Meeting of Board of Directors was held on Thursday, 31st July, 2025 at 03:30 p.m. The Board of Directors discussed and/or approved the attached points such as a) Unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories' board met on 31st July 2025 and approved the unaudited financial results for Q1 FY26 (quarter ended 30th June 2025). Revenue from operations fell to Rs. 156.61 lakhs from Rs. 174.66 lakhs in the same quarter last year, a decline of about 10%. Profit after tax dropped to Rs. 11.92 lakhs from Rs. 13.72 lakhs, with EPS at Rs. 0.47 vs Rs. 0.54 earlier. The board also approved the Director's Report, Management Discussion Report, and Corporate Governance Report for FY25. Mr. Swapnil Jayeshbhai Madiyar was recommended as a new Non-Executive Director, and Mr. N.K. Menon was re-appointed as Whole Time Director & CEO for one more year. The 39th Annual General Meeting was fixed for 30th September 2025 via video conference.
The year-on-year decline in both revenue and profit signals weak quarterly performance, which may be viewed negatively by investors. However, the appointment and continuity of leadership bring some stability. Shareholders should watch whether the company can reverse the downward trend in the coming quarters.